ClinConnect ClinConnect Logo
Search / Trial NCT05274334

Measurement of Lipogenic Flux by Deuterium Resolved Mass Spectrometry Via Non-invasive Breath Analysis

Launched by UNIVERSITY CHILDREN'S HOSPITAL BASEL · Mar 1, 2022

Trial Information

Current as of June 22, 2025

Completed

Keywords

Deuterium Resolved Mass Spectrometry Exhaled Breath Deuterium Enrichment Metabolome Of Exhaled Breath Deuterated Exhaled Metabolites

ClinConnect Summary

The study objective is to measure the DNL by ingestion of a single oral dose of 70% 2H2O at 2 g/kg body-water. The subjects will consume a Yoghurt consisting of 300g of 'Excellence Joghurt Nature gezuckert' which contains 410 Kcal, 28g fat, 34g carbohydrates and 9g protein. The exhaled air of the subjects will be measured several times per hour to analyse de novo lipogenesis (DNL) non-invasive by deuterium resolved mass spectrometry.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Healthy adult volunteers
  • English speaking, or good knowledge of the English language
  • Able to understand the study
  • Able to give informed consent
  • Exclusion Criteria:
  • Current pregnancy

About University Children's Hospital Basel

The University Children's Hospital Basel is a leading pediatric healthcare institution committed to advancing child health through innovative research and clinical excellence. As a prominent clinical trial sponsor, the hospital focuses on developing and evaluating new therapies and interventions tailored to the unique needs of children. With a multidisciplinary team of experienced pediatricians, researchers, and healthcare professionals, the hospital fosters a collaborative environment that prioritizes patient safety and ethical standards. By engaging in cutting-edge clinical trials, the University Children's Hospital Basel aims to enhance treatment options and improve outcomes for pediatric patients, contributing to the broader field of child health and medicine.

Locations

Basel, , Switzerland

Patients applied

0 patients applied

Trial Officials

Pablo Sinues, Prof. Dr.

Principal Investigator

Universitäts-Kinderspital beider Basel (UKBB)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials